Literature DB >> 1827559

Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma.

C D Schiller1, M R Schneider, H Hartmann, A H Graf, H Klocker, G Bartsch.   

Abstract

Adrenal androgens are discussed as a reason for tumor progression after androgen ablation therapy. Because of the difference in the secretion of androgens by the adrenals of humans and rats, there is no reliable tumor model to study the role of adrenal androgens in tumor progression. Therefore, the main adrenal androgens were administered to rats in order to mimic human endocrine conditions. Application of dehydroepiandrosteron-sulfate (DHEA-S) alone or a mixture of androstendione (A), 11 beta-hydroxyandrostendione (OHA), dehydroepiandrosterone (DHEA), and its sulfate (DHEA-S) to castrated rats caused only a slight increase of prostate and seminal vesicle weight. Contrary to these findings, growth of the R3327 prostatic carcinoma in castrated rats was greatly stimulated by these adrenal androgens up to the level of the intact control. Thus, in spite of androgen ablation, tumor progression could be induced by exogenous adrenal androgens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827559     DOI: 10.1007/bf00294013

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  19 in total

Review 1.  Endocrine control and physiology of the prostate.

Authors:  A A Sandberg
Journal:  Prostate       Date:  1980       Impact factor: 4.104

2.  Biological significance of measurable androgen levels in the rat ventral prostate following castration.

Authors:  N Kyprianou; J T Isaacs
Journal:  Prostate       Date:  1987       Impact factor: 4.104

3.  Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro.

Authors:  M E Harper; A Pike; W B Peeling; K Griffiths
Journal:  J Endocrinol       Date:  1974-01       Impact factor: 4.286

4.  In vitro metabolism of androgens in whole human blood.

Authors:  J Blaquier; E Forchielli; R I Dorfman
Journal:  Acta Endocrinol (Copenh)       Date:  1967-08

5.  Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.

Authors:  M Moguilewsky; J Fiet; C Tournemine; J P Raynaud
Journal:  J Steroid Biochem       Date:  1986-01       Impact factor: 4.292

6.  Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.

Authors:  W J Ellis; J T Isaacs
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

7.  Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.

Authors:  J M Brisset; L Boccon-Gibod; H Botto; M Camey; G Cariou; J M Duclos; F Duval; D Gontiès; R Jorest; L Lamy
Journal:  Prog Clin Biol Res       Date:  1987

8.  Androgen and precursor levels in serum and testes of adult rats under basal conditions and after hCG stimulation.

Authors:  U Punjabi; J P Deslypere; L Verdonck; A Vermeulen
Journal:  J Steroid Biochem       Date:  1983-10       Impact factor: 4.292

9.  Antitumor activity of antiestrogenic phenylindoles on experimental prostate tumors.

Authors:  M R Schneider; E von Angerer; W Höhn; F Sinowatz
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

10.  Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.

Authors:  J T Isaacs; D S Coffey
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

View more
  4 in total

Review 1.  Androgen signal transduction and prostatic carcinoma.

Authors:  H Klocker; Z Culig; F Kaspar; A Hobisch; J Eberle; A Reissigl; G Bartsch
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 2.  Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.

Authors:  Elahe A Mostaghel; Peter S Nelson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

3.  Effect of zindoxifene on experimental prostatic tumours of the rat.

Authors:  M R Schneider; C D Schiller; A Humm; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Steroid hormone synthetic pathways in prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Transl Androl Urol       Date:  2013-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.